Lilly and the William Sansum Diabetes Center announce a five-year research collaboration

PR Newswire — March 23, 2017

SANTA BARBARA, Calif. and INDIANAPOLIS, March 23, 2017 /PRNewswire/ — Eli Lilly
and Company (NYSE: LLY) and the William Sansum Diabetes Center have established
a research collaboration to improve the lives of Latino people affected by
diabetes through enhanced research, education and care.

“The tremendous burden of diabetes and cardiovascular disease bears a
disproportionate weight on Latino families in the United States,” said David
Kerr, M.D., FRCPE, director of Innovation and Research for the William Sansum
Diabetes Center. “This collaboration with Lilly will allow us to gain a better
understanding of how we can help these families.”

Dr. Kerr added that Latino people comprise 43% of the total population in Santa
Barbara County, and rates of cardio-metabolic disease are persistently higher
than in the rest of the population due to a combination of factors beyond
biological risk, including economics, culture and education.

For Lilly, the collaboration will provide valuable insights into patients’ unmet
needs and aid in the development of interventions that could improve health
outcomes for Latino people.

“This is a great opportunity for us to further understand the significant impact
of diabetes for Latino families,” said Dara Schuster, M.D., senior director of
U.S. Medical Affairs for Lilly Diabetes. “Through this collaboration, we will
learn where the gaps are so we can develop meaningful solutions for the unmet

About William Sansum Diabetes Center
The William Sansum Diabetes Center has been on the cutting edge of diabetes
research, clinical care, and education since its founding in 1944 by Dr. William
Sansum, the first U.S. physician to administer insulin in the treatment of
diabetes. The Center has developed new technologies and produced groundbreaking
diabetes treatments, such as the artificial pancreas automating delivery of
insulin to patients and new protocols for the management of pregnancies
complicated by diabetes. Today, the Center has international recognition for
research and innovation in the creation, development, and application of novel
and effective smart technologies. The Center is committed to developing
effective approaches to the education of clinicians, people with diabetes and
their families, and healthcare providers in partnership with academic
institutions, specialist diabetes centers, and primary care colleagues. For more
information, please visit

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced
the world’s first commercial insulin. Today we are building upon this heritage
by working to meet the diverse needs of people with diabetes and those who care
for them. Through research and collaboration, a wide range of therapies and a
continued determination to provide real solutions–from medicines to support
programs and more–we strive to make life better for all those affected by
diabetes around the world. For more information, visit or
follow us on Twitter: @LillyDiabetes.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make
life better for people around the world. We were founded more than a century ago
by a man committed to creating high-quality medicines that meet real needs, and
today we remain true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to those who need
them, improve the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more about Lilly,
please visit us at and

Refer to: David Kerr, MD Julie Williams

William Sansum Diabetes Center Eli Lilly and Company

(805) 682-7640 Ext. 241 (317) 627-4056

To view the original version on PR Newswire,

SOURCE Eli Lilly and Company

Subject Codes: PC/t.170323120001270, PT/lang.en, PC/ticker, IN/HEA,
IN/PHA, IN/MTC, SU/JVN, SU/HSP, RE/California,
RE/Indiana, PC/priority.r, PC/category.f,
PC/DataFeat_calif, PC/DataFeat_indpr, PC/DataFeat_natl3,
PC/port_32, PC/class.1019, PC/WAVO_c….., PC/APT_c….,
PC/state_c, PC/wavo1_c, PC/class.1245, PC/WAVO_….h.,
PC/APT_….h, PC/trade_h, PC/wavo5_h, PC/class.1030,
PC/WAVO_l….., PC/APT_l…., PC/state_l, PC/wavo1_l,
PC/class.1000, PC/WAVO_..b…, PC/APT_..b..,
PC/circuit_b, PC/wavo3_b, PC/Billing_AAR, PC/Billing_H04,
PC/Billing_LVH, PC/Billing_RWB, PC/Billing_TNW,
PC/Billing_US1, PC/1stAcc_916319, PC/OtherAcc_916306,
PC/bureau_DE, PC/port_01, PC/port_96, PC/port_31,
PC/port_19, PC/port_91, PC/website, PC/photo,

Company Codes: NYSE:LLY

Leave a Reply

Fatal error: Call to undefined function show_subscription_checkbox() in /home3/steer/public_html/ on line 95